Status:

COMPLETED

Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)

Lead Sponsor:

Nymox Corporation

Conditions:

Benign Prostatic Hyperplasia

Eligibility:

MALE

45+ years

Phase:

PHASE3

Brief Summary

This study will evaluate the safety and efficacy of a 2.5 mg dose of NX-1207 for the treatment of BPH (benign prostatic hyperplasia) as compared to placebo.

Eligibility Criteria

Inclusion

  • Provide signed informed consent prior to enrolment in the study
  • IPSS ≥ 15
  • Prostate Volume ≥ 30 mL ≤ 70 mL
  • Qmax \< 15 mL/sec based on a minimum void of 125 mL
  • Agree not to use any other approved or experimental BPH or OAB medication anytime during the study

Exclusion

  • History of illness or condition that may interfere with study or endanger subject
  • Use of prescribed medications that may interfere with study or endanger subject
  • Presence of a median lobe of the prostate
  • Previous surgery or MIST for treatment of BPH
  • Post-void residual urine volume \> 200 mL
  • PSA ≥ 10 ng/mL; prostate cancer must be ruled out (negative biopsy) for PSA ≥ 4 ng/mL
  • Participation in a study of any investigational drug or device within the previous 90 days
  • Prostate cancer

Key Trial Info

Start Date :

April 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 1 2013

Estimated Enrollment :

500 Patients enrolled

Trial Details

Trial ID

NCT00918983

Start Date

April 1 2009

End Date

November 1 2013

Last Update

April 30 2014

Active Locations (41)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 11 (41 locations)

1

For information concerning this clinical site, please contact Nymox at 800-936-9669

Birmingham, Alabama, United States, 35209

2

For information concerning this clinical site, please contact Nymox at 800-936-9669.

Huntsville, Alabama, United States, 35801

3

For information concerning this clinical site, please contact Nymox at 800-936-9669.

Tucson, Arizona, United States, 85712

4

For information concerning this clinical site, please contact Nymox at 800-936-9669.

Little Rock, Arkansas, United States, 72211

Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) | DecenTrialz